Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by 1832 Asset Management L.P.

1832 Asset Management L.P. increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,417 shares of the medical equipment provider’s stock after acquiring an additional 1,597 shares during the quarter. 1832 Asset Management L.P.’s holdings in Hologic were worth $2,137,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Canada Pension Plan Investment Board boosted its holdings in shares of Hologic by 72.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 453,913 shares of the medical equipment provider’s stock worth $35,387,000 after purchasing an additional 190,881 shares during the last quarter. Rodgers Brothers Inc. raised its holdings in Hologic by 3.6% in the 1st quarter. Rodgers Brothers Inc. now owns 104,243 shares of the medical equipment provider’s stock valued at $8,127,000 after buying an additional 3,645 shares during the period. Shell Asset Management Co. boosted its stake in shares of Hologic by 68.6% in the 1st quarter. Shell Asset Management Co. now owns 10,517 shares of the medical equipment provider’s stock valued at $820,000 after buying an additional 4,279 shares during the period. Twin Capital Management Inc. grew its stake in shares of Hologic by 11.2% during the first quarter. Twin Capital Management Inc. now owns 37,105 shares of the medical equipment provider’s stock worth $2,893,000 after purchasing an additional 3,738 shares in the last quarter. Finally, National Bank of Canada FI boosted its holdings in Hologic by 352.0% in the first quarter. National Bank of Canada FI now owns 299,098 shares of the medical equipment provider’s stock valued at $22,474,000 after purchasing an additional 232,928 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Argus upped their price objective on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Evercore ISI lowered their price objective on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a research note on Tuesday, July 2nd. Stephens started coverage on Hologic in a research report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Friday, May 3rd. Finally, Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.55.

Hologic Trading Up 1.0 %

Shares of HOLX stock traded up $0.75 during trading hours on Friday, reaching $78.63. 1,472,174 shares of the stock traded hands, compared to its average volume of 1,435,837. The business has a fifty day moving average price of $74.56 and a 200 day moving average price of $75.01. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.31. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $18.35 billion, a PE ratio of 40.12, a PEG ratio of 2.62 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the company earned $1.06 earnings per share. The company’s revenue for the quarter was down .8% on a year-over-year basis. On average, equities research analysts forecast that Hologic, Inc. will post 4.08 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.